Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Roquefort Investments PLC ( (GB:ROQ) ) just unveiled an update.
Roquefort Therapeutics plans to acquire worldwide exclusive rights to AO-252, a TACC3-targeting oncology drug candidate from Coiled Therapeutics and A2A Pharmaceuticals, while completing an associated equity fundraise and preparing documentation for admission to the London Stock Exchange’s AIM market. The company has formally initiated the process to delist its ordinary shares from the FCA’s Official List and the London Stock Exchange Main Market, with AIM readmission and completion of the AO-252 transaction expected to follow, signalling a strategic shift towards a growth-focused market segment and an expanded oncology pipeline.
Coiled Therapeutics, which holds the AO-252 rights, has advanced the brain-penetrant small molecule through pre-clinical work, IND approval and into an active Phase I trial in the U.S. for patients whose cancers have progressed on other treatments. A2A Pharma, Coiled’s parent and an AI-driven drug discovery company, has a track record of spinning out oncology assets, underscoring the potential strategic value of AO-252 for Roquefort’s future development plans.
The most recent analyst rating on (GB:ROQ) stock is a Sell with a £1.00 price target. To see the full list of analyst forecasts on Roquefort Investments PLC stock, see the GB:ROQ Stock Forecast page.
Spark’s Take on GB:ROQ Stock
According to Spark, TipRanks’ AI Analyst, GB:ROQ is a Neutral.
The score is primarily held back by weak financial fundamentals (pre-commercial revenue volatility, ongoing losses and cash burn). Technical indicators also point to a sustained downtrend. Low leverage on the balance sheet provides some support, but the negative P/E and lack of dividend yield limit valuation appeal.
To see Spark’s full report on GB:ROQ stock, click here.
More about Roquefort Investments PLC
Roquefort Therapeutics plc is a London-listed biotechnology company focused on developing novel cancer therapeutics for indications with significant unmet medical need. The company is active in oncology drug development and is expanding its pipeline through partnerships and licensing arrangements with clinical-stage innovators and AI-driven discovery platforms.
Average Trading Volume: 1,620,277
Technical Sentiment Signal: Sell
Current Market Cap: £1.8M
See more data about ROQ stock on TipRanks’ Stock Analysis page.